Buprenorphine (Suboxone, Sublocade) prior authorization at Blue Cross Blue Shield of Michigan
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Blue Cross Blue Shield of Michigan requires prior-authorization documentation for Buprenorphine (Suboxone, Sublocade): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Blue Cross Blue Shield of Michigan reviews Buprenorphine (Suboxone, Sublocade) prior authorizations against its medical policy . Blue Cross Blue Shield of Michigan-specific context: Largest insurer in Michigan (~4.5M members). Statutory non-profit mutual. Switched PBM from Express Scripts to OptumRx effective January 2024 — appeals around 2024-2025 may involve formulary disruption. Michigan DIFS oversight.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Blue Cross Blue Shield of Michigan's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Step therapy via OptumRx (PBM since 2024)
- Site-of-care reductions for infusions
- Behavioral health prior auth
- OON balance bill disputes
Buprenorphine (Suboxone, Sublocade)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Step therapy requiring sublingual before long-acting injectable
- Specialty pharmacy restriction
- Frequency reduction
Marketed as Suboxone, Subutex (sublingual), Sublocade (monthly injectable), Brixadi (weekly/monthly injectable). Federal Medicaid required coverage.
Manufacturer patient-assistance program: Indivior INSUPPORT — relevant when a Blue Cross Blue Shield of Michigan denial sticks and the patient needs bridge access while appealing.
How Blue Cross Blue Shield of Michigan approaches Medications for Opioid Use Disorder (MOUD) PAs
For Buprenorphine, check whether the current Blue Cross Blue Shield of Michigan Medications for Opioid Use Disorder (MOUD) policy cites behavioral health prior auth. Pharmacy-benefit review for Buprenorphine at Blue Cross Blue Shield of Michigan is routed through OptumRx (switched from Express Scripts January 2024). The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Blue Cross Blue Shield of Michigan; if denied, use the filing date and route printed on that denial notice. MHPAEA non-quantitative-treatment-limitation analysis applies — request Blue Cross Blue Shield of Michigan's written NQTL comparative analysis under the 2023 final rule when the MOUD denial appears stricter than comparable medical-side prior auth. Blue Cross Blue Shield of Michigan is domiciled in MI, so unresolved appeals escalate to the MI insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://providers.bcbsm.com) with the same packet plus an applicable, current clinical source supporting Buprenorphine (Suboxone, Sublocade)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Blue Cross Blue Shield of Michigan denial on DenialHelp.
Contact Blue Cross Blue Shield of Michigan
- Provider portal: https://providers.bcbsm.com
Frequently asked questions
What documentation does Blue Cross Blue Shield of Michigan need for Buprenorphine (Suboxone, Sublocade) prior auth?
Blue Cross Blue Shield of Michigan's typical PA packet for Buprenorphine (Suboxone, Sublocade): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Blue Cross Blue Shield of Michigan?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for Buprenorphine (Suboxone, Sublocade) at Blue Cross Blue Shield of Michigan?
Preparation scenarios to check against the current notice and policy include: Step therapy via OptumRx (PBM since 2024); Site-of-care reductions for infusions; Behavioral health prior auth. These are not measured frequency claims. For Buprenorphine (Suboxone, Sublocade), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Can Blue Cross Blue Shield of Michigan apply step therapy to MOUD like Buprenorphine?
MHPAEA prohibits non-quantitative treatment limitations on MOUD that are stricter than the limits on comparable medical/surgical benefits. Request Blue Cross Blue Shield of Michigan's written NQTL comparative analysis under the 2023 MHPAEA final rule. State Medicaid MCO plans are additionally required to cover all FDA-approved MOUD products without step therapy under the SUPPORT Act (2018) and related state plan amendments. Pharmacy-benefit handling is routed through OptumRx (switched from Express Scripts January 2024). External-review escalation for Blue Cross Blue Shield of Michigan fully-insured policies sits with the MI insurance department.
How do I prep for a peer-to-peer with Blue Cross Blue Shield of Michigan on Buprenorphine (Suboxone, Sublocade)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
- Adalimumab at Blue Cross Blue Shield of Michigan
- Aflibercept at Blue Cross Blue Shield of Michigan
- Apixaban at Blue Cross Blue Shield of Michigan
- Atezolizumab at Blue Cross Blue Shield of Michigan
- Buprenorphine (Suboxone, Sublocade) at UnitedHealthcare
- Buprenorphine (Suboxone, Sublocade) at Elevance Health
- Buprenorphine (Suboxone, Sublocade) at Aetna
Generate the Buprenorphine (Suboxone, Sublocade) PA packet
Open ApprovalHelp — generate a Buprenorphine (Suboxone, Sublocade) prior-auth packet tailored to Blue Cross Blue Shield of Michigan's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com